Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730157 · ClinicalTrials.gov registry record · Early Phase 1
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
A Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT01730157 is a Early Phase 1 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 6 participants.
The verdict
NCT01730157, a Early Phase 1 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This pilot clinical trial studies radioembolization and ipilimumab in treating patients with uveal melanoma with liver metastases. Radioembolization kills tumor cells by blocking the blood flow to the tumor and keeping radioactive substances near the tumor. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radioembolization together with ipilimumab may kill more tumor cells in patients with uveal melanoma
Interventions
- OTHER laboratory biomarker analysis
- RADIATION yttrium Y 90 glass microspheres
- BIOLOGICAL ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-12 |
| Est. Completion | 2016-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01730157
The ClinicalTrials.gov registry entry for NCT01730157 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01730157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01730157 about?
NCT01730157 is a clinical study titled "Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases". This pilot clinical trial studies radioembolization and ipilimumab in treating patients with uveal melanoma with liver metastases. Radioembolization kills tumor cells by blocking the blood flow to the tumor and keeping radioactive substances near the tumor. Monoclonal antibodies, such as ipilimumab,...
What is the current status of trial NCT01730157?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2012-12. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01730157?
The interventions under investigation include: laboratory biomarker analysis (OTHER), yttrium Y 90 glass microspheres (RADIATION), ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01730157?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.